ProMetic Life Sciences Inc. (TSE:PLI) had its target price lifted by equities researchers at Canaccord Genuity from C$4.50 to C$4.75 in a research report issued on Friday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 77.90% from the company’s current price.

Several other equities analysts have also recently weighed in on the company. Scotiabank reissued an “outperform” rating and issued a C$5.00 price target on shares of ProMetic Life Sciences in a research note on Tuesday, August 16th. Royal Bank Of Canada restated an “outperform” rating on shares of ProMetic Life Sciences in a report on Friday, October 21st. TD Securities restated a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a report on Wednesday, September 28th. Finally, Bloom Burton restated a “hold” rating on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. ProMetic Life Sciences currently has a consensus rating of “Buy” and a consensus price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) opened at 2.67 on Friday. The firm’s 50-day moving average is $2.88 and its 200 day moving average is $2.93. ProMetic Life Sciences has a 12-month low of $1.88 and a 12-month high of $3.62. The firm’s market cap is $1.61 billion.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.